Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$146.50 USD
-0.62 (-0.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $146.42 -0.08 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$146.50 USD
-0.62 (-0.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $146.42 -0.08 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Zacks News
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COLL or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. NBIX: Which Stock Is the Better Value Option?
COLL or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. NBIX: Which Stock Is the Better Value Option?
Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.32% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group
5 Top Stocks Set to Beat Earnings Estimates Next Week
by Nalak Das
Although, expectations for fourth-quarter 2019 earnings are negative at present, results so far are far better than initially anticipated.
Bet on Earnings Beat With 5 Top-Ranked Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
by Zacks Equity Research
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
AMRX vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. NBIX: Which Stock Is the Better Value Option?
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Breakout Stocks of the Last Decade to Consider for 2020
by Christopher Vargas
The 2010s were a fruitful decade for investors as the S&P 500 has surged over 189% so far.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)
by Zacks Equity Research
Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4
by Sweta Killa
Investors could be well served by ETFs and stocks from sectors that house top-ranked industries.
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CTLT or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HKMPF vs. NBIX: Which Stock Is the Better Value Option?
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.